Search

Displaying results 3951 - 3960 of 5925 in total
  1. Drug

    Mezepine

    go.drugbank.com/drugs/DB21047
    Experimental

    Mezepine has a monoisotopic molecular weight of 266.18 Da.

  2. Drug

    Etarotene

    go.drugbank.com/drugs/DB21071
    Experimental

    Etarotene has a monoisotopic molecular weight of 396.21 Da.

  3. Drug

    Pinolcaine

    go.drugbank.com/drugs/DB21159
    Experimental

    Pinolcaine has a monoisotopic molecular weight of 351.22 Da.

  4. Drug

    Lorcinadol

    go.drugbank.com/drugs/DB21160
    Experimental

    Lorcinadol has a monoisotopic molecular weight of 314.13 Da.

  5. Drug

    Linarotene

    go.drugbank.com/drugs/DB21165
    Experimental

    Linarotene has a monoisotopic molecular weight of 398.2 Da.

  6. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR

  7. Drug

    Vabametkib

    go.drugbank.com/drugs/DB21629
    Investigational

    Vabametkib has a monoisotopic molecular weight of 566.3 Da.

  8. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with

  9. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    [L17040] Due to a range of its molecular properties - namely its anti-apoptotic effects - tauroursodeoxycholic acid has been examined in inflammatory metabolic diseases and neurodegenerative diseases.

  10. Drug

    Ceftobiprole

    go.drugbank.com/drugs/DB04918
    ApprovedWithdrawn

    Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European Union primarily due